Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended				9 Months Ended
	Jan. 31, 2015		Jan. 31, 2014		Jan. 31, 2015		Jan. 31, 2014
Net revenue	$ 1,829		$ 3,690		$ 5,622		$ 9,092
Sales and marketing costs	(1,094)		(821)		(3,340)		(2,160)
Stock- based compensation expense	(657)		(941)		(2,284)		(1,968)
Personalized Oncology Solutions [Member]
Net revenue	453		590		1,245		1,834
Direct cost of services	(672)		(608)		(2,171)		(2,078)
Sales and marketing costs	(366)		(405)		(1,243)		(1,159)
Other operating expenses	0		0		0		0
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	(585)		(423)		(2,169)		(1,403)
Translational Oncology Solutions [Member]
Net revenue	1,376		3,100		4,377		7,258
Direct cost of services	(1,300)		(1,007)		(3,205)		(2,572)
Sales and marketing costs	(613)		(352)		(1,650)		(812)
Other operating expenses	(1,028)		(531)		(3,490)		(1,595)
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	(1,565)		1,210		(3,968)		2,279
Unallocated Corporate Overhead [Member]
Net revenue	0		0		0		0
Direct cost of services	0		0		0		0
Sales and marketing costs	0		0		0		0
Other operating expenses	(612)		(1,254)		(2,413)		(2,790)
Stock- based compensation expense	(657)	[1]	(941)	[1]	(2,284)	[1]	(1,968)	[1]
Segment profit (loss)	(1,269)		(2,195)		(4,697)		(4,758)
Consolidated [Member]
Net revenue	1,829		3,690		5,622		9,092
Direct cost of services	(1,972)		(1,615)		(5,376)		(4,650)
Sales and marketing costs	(979)		(757)		(2,893)		(1,971)
Other operating expenses	(1,640)		(1,785)		(5,903)		(4,385)
Stock- based compensation expense	(657)	[1]	(941)	[1]	(2,284)	[1]	(1,968)	[1]
Segment profit (loss)	$ (3,419)		$ (1,408)		$ (10,834)		$ (3,882)

[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.